FDA rejects combo cholesterol drug

March 7th, 2012 - 11:04 pm ICT by Aishwarya Bhatt  

New York, Mar 7 (THAINDIAN NEWS) Merck & Co Inc has announced that the Food and Drugs Administration has failed to approve its combination cholesterol pill. The company announced that the FDA is requesting more data on the drug but they stopped short of revealing what kind of data was required.

The drug, which contains a generic version of Pfizer’s mega drug Lipitor, regulates the level of bad cholesterol in the body. A cholesterol lowering drug will undoubtedly help push the sale of Merck.

When Pfizer launched Lipitor, the drug quickly became the world’s best selling drug. At its peak, the annual sale reached $13 billion. The sale however declined when Pfizer lost the patent in 2011.

Merck has however revealed that they are addressing the concerns of the FDA. The company said that they will come out with new data later in the year which they believe will help the FDA to address the outstanding issues.

The company indicated that they will meet with the FDA and discuss the next steps necessary to get the drugs on the market.

Merck’s Zetia, which is also considered a blockbuster drug, lowers the level of bad cholesterol but the company is scheduled to lose the patent in 2017.

Related Stories

Tags: , , , , , , , , , , , , , , , ,

Posted in Health |

Subscribe